Latest news

• Trial combining British and Russian COVID-19 vaccines could begin in February

  On 11 December 2020, AZ announced "a clinical trial programme to assess the safety and immunogenicity of a combination of AZD1222, developed by AstraZeneca and Oxford University, and Sputnik V, developed ... The interim analysis for efficacy of the

• COVID-19 vaccine developers respond to new strain

  British pharma company AstraZeneca also told Reuters that its COVID-19 vaccine, AZD1222, should be effective against the new variant. ... AZD1222 contains the genetic material of the SARS-CoV-2 virus spike protein, and the changes to the genetic code

• The Lancet confirms effectiveness of AZ/Oxford University's COVID-19 vaccine

  In the control group – those who did not receive AZD1222 – ten participants were hospitalised due to COVID-19, with two volunteers developing severe disease, including one fatal case. ... The company will also continue to evaluate AZD1222 in a large

• AZ divests European rights for cholesterol med Crestor to Grünenthal

  Last month, AZ announced that the Oxford University-partnered vaccine candidate AZD1222 demonstrated an average efficacy of 70%, with up to 90% efficacy in a subgroup who received a half dose

• AZ, Oxford University face more scrutiny over COVID-19 vaccine data

  WHO’s immunisations director says ‘more than a press release’ is needed